Publications by authors named "John Mendelsohn"

61Publications

Rare, Intense, Big fires dominate the global tropics under drier conditions.

Sci Rep 2017 10 30;7(1):14374. Epub 2017 Oct 30.

Research and Information Services of Namibia (RAISON), PO Box, 1405, Windhoek, Namibia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-14654-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662699PMC
October 2017

ALK: a tyrosine kinase target for cancer therapy.

Cold Spring Harb Mol Case Stud 2017 Jan;3(1):a001115

Department of Thoracic/Head and Neck, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/mcs.a001115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5171696PMC
January 2017

Clinical Use of Precision Oncology Decision Support.

JCO Precis Oncol 2017 13;2017. Epub 2017 Sep 13.

Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.17.00036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179148PMC
September 2017

Commentary on "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" (A Follow Up).

Authors:
John Mendelsohn

Cancer Res 2016 09;76(18):5192-4

Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-16-2269DOI Listing
September 2016

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel.

Oncotarget 2016 Nov;7(44):71686-71695

Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.11994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342111PMC
November 2016

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.

JAMA Oncol 2016 Nov;2(11):1452-1459

Center for Personalized Cancer Therapy, Division of Hematology and Oncology, University of California, San Diego3Worldwide Innovative Network for Personalized Cancer Therapy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.2129DOI Listing
November 2016

Response.

J Natl Cancer Inst 2016 Mar 24;108(3):djw001. Epub 2016 Feb 24.

Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA, USA (MS and RZ); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (JJL and CW); The University of Texas MD Anderson Cancer Center, Houston, USA (JM); American Society of Clinical Oncology, Alexandria, VA, USA (RLS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw001DOI Listing
March 2016

Reply to M.P. Decatris et al.

J Clin Oncol 2016 Mar 11;34(8):886. Epub 2016 Jan 11.

The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.2479DOI Listing
March 2016

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

J Natl Cancer Inst 2015 Nov 15;107(11). Epub 2015 Sep 15.

Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas, Sao Paulo, Brazil (DLFJ); Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DLFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA (MS, RK); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX (CW, JJL); Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX (DSH); Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud, Villejuif, France (AME, VL); Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France (AME, RLS, JM, VL, RK); American Society of Clinical Oncology, Alexandria, VA (RLS); The University of Texas MD Anderson Cancer Center, Houston, TX (JM).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/107/11/djv253.full.pd
Web Search
http://jnci.oxfordjournals.org/content/108/3/djv430.full.pdf
Web Search
http://jnci.oxfordjournals.org/lookup/doi/10.1093/jnci/djv25
Publisher Site
http://dx.doi.org/10.1093/jnci/djv253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857149PMC
November 2015

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

J Clin Oncol 2015 Nov 24;33(32):3817-25. Epub 2015 Aug 24.

Maria Schwaederle, Melissa Zhao, and Razelle Kurzrock, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, CA; J. Jack Lee and John Mendelsohn, The University of Texas MD Anderson Cancer Center, Houston, TX; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Alexander M. Eggermont and Vladimir Lazar, Institut Gustave Roussy, University Paris-Sud; and Alexander M. Eggermont, Richard L. Schilsky, John Mendelsohn, Vladimir Lazar, and Razelle Kurzrock, Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/32/3817.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.61.5997
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.5997DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737863PMC
November 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.

Drug Discov Today 2015 Dec 3;20(12):1433-8. Epub 2015 Jul 3.

Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2015.05.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648066PMC
December 2015

A decision support framework for genomically informed investigational cancer therapy.

J Natl Cancer Inst 2015 Jul 11;107(7). Epub 2015 Apr 11.

Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy , the University of Texas MD Anderson Cancer Center, Houston, TX (FMB, AJ, VH, AMB, JZ, KRS, JM, GBM); Departments of Investigational Cancer Therapeutics (FMB, LB, SAPP, DSH, AMT), Surgical Oncology (FMB), Hematopathology (MR, KPP), Bioinformatics & Computational Biology (KC), GI Medical Oncology (SK), Melanoma Medical Oncology (MAD), Experimental Therapeutics (RB), Systems Biology (AKE, GBM), the University of Texas MD Anderson Cancer Center, Houston, TX; School of Biomedical Informatics, the University of Texas Health Science Center, Houston, TX (EVB).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/107/7/djv098.full.pdf
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/djv098
Publisher Site
http://dx.doi.org/10.1093/jnci/djv098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651038PMC
July 2015

Innovative clinical trials for development of personalized cancer medicine.

Mol Oncol 2015 May 5;9(5):933-4. Epub 2015 Mar 5.

ASCO, American Society of Clinical Oncology, Alexandria, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2015.02.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528749PMC
May 2015

CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth.

Clin Cancer Res 2015 Jan;21(2):227-9

Helio Genetics, East Hanover, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2491DOI Listing
January 2015

The 2010 Institute of Medicine consensus statement "A national clinical trials network for the 21st century": progress and challenges.

Semin Oncol 2014 Aug 11;41(4):435-436. Epub 2014 Jun 11.

Dana-Farber/Brigham and Women's Cancer Center, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2014.06.003DOI Listing
August 2014

Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps.

Discov Med 2014 Feb;17(92):101-14

Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160907PMC
February 2014

Turning the tide against cancer through sustained medical innovation: the pathway to progress.

Clin Cancer Res 2014 Mar 12;20(5):1081-6. Epub 2014 Feb 12.

Authors' Affiliations: Center for Learning Healthcare, Duke Cancer Center Research Program, Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina; Personalized Medicine Coalition; and Pharmaceutical Research and Manufacturers of America, Washington, DC; Complex Adaptive Systems Initiative, School of Life Sciences, Arizona State University, Tucson, Arizona; M2Gen, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida; American Association for Cancer Research, Philadelphia, Pennsylvania; Opus Three LLC, Rockville, Maryland; Clinical Development and Medical Affairs, Eli Lilly and Company, Indianapolis, Indiana; Feinstein Kean Healthcare, Cambridge, Massachusetts; Global Strategic Market Access and Policy, Celgene Corporation, Summit, New Jersey; American Cancer Society, Atlanta, Georgia; The Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas; and Breast Oncology Program, Applied Genomics, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-3430DOI Listing
March 2014

Building a personalized medicine infrastructure at a major cancer center.

J Clin Oncol 2013 May 15;31(15):1849-57. Epub 2013 Apr 15.

University of Texas MD Anderson Cancer Center, 1400 Pressler St, FCT17.5030, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.3043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878103PMC
May 2013

Personalizing oncology: perspectives and prospects.

Authors:
John Mendelsohn

J Clin Oncol 2013 May 15;31(15):1904-11. Epub 2013 Apr 15.

The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 491, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.3605DOI Listing
May 2013

The impact of tumor heterogeneity on patient treatment decisions.

Clin Chem 2013 Jan 9;59(1):38-40. Epub 2012 Nov 9.

Sheikh Khalifa bin Zayed Al Nahyan Institute of Personalized Cancer Therapy-IPCT, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.clinchem.org/cgi/doi/10.1373/clinchem.2012.194712
Publisher Site
http://dx.doi.org/10.1373/clinchem.2012.194712DOI Listing
January 2013

Bioinformatics and systems biology.

Mol Oncol 2012 Apr 17;6(2):147-54. Epub 2012 Feb 17.

Department of Systems Biology, Institute for Personalized Cancer Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX 77054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2012.01.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345061PMC
April 2012

A national cancer clinical trials system for targeted therapies.

Authors:
John Mendelsohn

Sci Transl Med 2011 Mar;3(75):75cm8

University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3001716DOI Listing
March 2011

WIN Consortium--challenges and advances.

Nat Rev Clin Oncol 2011 Mar;8(3):133-4

The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2010.230DOI Listing
March 2011

Shaking up cancer clinical trials: an interview with John Mendelsohn, M.D., by Joanne Nicholas.

Authors:
John Mendelsohn

J Natl Cancer Inst 2010 Aug 6;102(16):1219-21. Epub 2010 Aug 6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djq320DOI Listing
August 2010

From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway.

Proc Natl Acad Sci U S A 2010 Mar 26;107(11):5118-23. Epub 2010 Feb 26.

David H Koch Center, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0915146107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841862PMC
March 2010

Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer.

Clin Genitourin Cancer 2009 Oct;7(3):E77-82

Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155876731170035
Publisher Site
http://dx.doi.org/10.3816/CGC.2009.n.028DOI Listing
October 2009

Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab.

Mol Cancer Ther 2008 May;7(5):1207-17

Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Unit 036, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-07
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-07-2187DOI Listing
May 2008

Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.

Cancer Res 2007 Sep;67(17):8240-7

Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-0589DOI Listing
September 2007

Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?

Proc Natl Acad Sci U S A 2006 Nov 7;103(46):17073-4. Epub 2006 Nov 7.

The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0608651103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1859890PMC
November 2006

EGF receptors as a target for cancer therapy.

Authors:
John Mendelsohn

Trans Am Clin Climatol Assoc 2004 ;115:249-53; discussion 253-4

The University of Texas MD Anderson Cancer Center,Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2263769PMC
April 2009

Epidermal growth factor receptor targeting in cancer.

Semin Oncol 2006 Aug;33(4):369-85

The University of Texas, MD Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2006.04.003DOI Listing
August 2006

The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression.

Oncogene 2005 Jun;24(27):4433-41

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 036, 1515 Holcombe Blvd., Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1208625DOI Listing
June 2005

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.

J Clin Oncol 2003 Jul;21(14):2787-99

University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.01.504DOI Listing
July 2003

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.

Oncogene 2003 May;22(21):3205-12

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1206394DOI Listing
May 2003

Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic.

Authors:
John Mendelsohn

Cancer Immunol Immunother 2003 May 14;52(5):342-6. Epub 2003 Mar 14.

The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-002-0354-7DOI Listing
May 2003

The role of growth factor signaling in malignancy.

Cancer Treat Res 2003 ;115:19-72

University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/0-306-48158-8_2DOI Listing
July 2003

Targeting the epidermal growth factor receptor for cancer therapy.

Authors:
John Mendelsohn

J Clin Oncol 2002 Sep;20(18 Suppl):1S-13S

University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
September 2002